Recent News

• 03.31.2026 - Virax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical Validation
• 12.04.2025 - Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement
• 12.03.2025 - Virax Biolabs Group Limited Announces $5 Million Private Placement
• 12.03.2025 - Virax Biolabs’ CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders
• 12.03.2025 - Virax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders

Recent Filings

• 03.20.2026 - 3 Initial statement of beneficial ownership of securities
• 03.18.2026 - 3 Initial statement of beneficial ownership of securities
• 03.18.2026 - 3 Initial statement of beneficial ownership of securities
• 03.18.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.18.2026 - 3 Initial statement of beneficial ownership of securities
• 03.18.2026 - 3 Initial statement of beneficial ownership of securities
• 02.17.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 01.30.2026 - EX-99.1 EX-99.1
• 01.30.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 12.31.2025 - 424B3 Prospectus [Rule 424(b)(3)]